This latter role is supported by the association between prolactin/PRLR down-regulation and significantly better survival outcome in patients with breast cancer [88, 102–105], which is consistent with the lack of anti-tumorigenic effects and therapeutic benefits observed in clinical trials with PRLR antagonists [106]. This evidence concerns the gene PRLR and breast cancer.